Tag: ado-trastuzumab emtansine
Looking Ahead to 2020: Global Antibody-drug Market Prediction
Cytotoxic drugs used in the treatment of solid tumors and hematological malignancies have, over the last 50 years, changed the natural progression of these...
ADAPT Study Shows Promising Results in the Treatment of Patients with...
Results from the German phase II ADAPT study (WSG-ADAPT), showed that neoadjuvant ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) is effective in the treatment of HER2-positive,...
XMT-1522 Demonstrates Potent Activity in Low HER2-Expressing Tumor Models
Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...
HER2+ Metastatic Breast Cancer and CNS metastases: A Retrospective, Exploratory Analysis...
The development of targeted antibody-drug conjugates (ADC) for the treatment of cancer represents a significant - and promising - progress. ADCs are precise and...
From the Editors: Welcome to a New Publication – ADC Review/Journal...
Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...
